查找临床试验
已按「荨麻疹」检索，对应国际通用词 chronic urticaria
共找到 25 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 00:19，每 5 分钟自动同步正在招募IV 期NCT05916937
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
Denmark
年龄 18 Years – 不限
Simon Francis Thomsen
正在招募II 期中国有中心NCT07219615
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
United States、Bulgaria、Canada、China、Germany 等 10 国
年龄 18 Years – 不限
Pfizer
正在招募不适用NCT04334031
Deployment o the Multidisciplinary Prospective Cohort Imminent
France
年龄 18 Years – 不限
University Hospital, Lille
正在招募II 期中国有中心NCT07415551
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Bulgaria、China、Poland、South Korea
年龄 18 Years – 75 Years
Yuhan Corporation
正在招募III 期中国有中心NCT07816328
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Hong Kong、Japan、South Korea
年龄 18 Years – 不限
Novartis Pharmaceuticals
正在招募不适用NCT07021495
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Netherlands
年龄 18 Years – 不限
Leiden University Medical Center
正在招募不适用NCT07358364
Remibrutinib in Real-world Clinical Practice
United States
年龄 18 Years – 不限
Novartis Pharmaceuticals
正在招募不适用NCT07642557
Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
Germany
年龄 18 Years – 不限
Novartis Pharmaceuticals
正在招募不适用NCT07328178
Analysis of the Role of IgE Proteoforms in Health and Disease
Belgium
年龄 18 Years – 不限
KU Leuven
正在招募不适用NCT07359430
Deep Phenotyping of CIndU
Netherlands
年龄 18 Years – 不限
Centre for Human Drug Research, Netherlands
正在招募不适用NCT07652944
Trial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain.
United States
年龄 18 Years – 64 Years
Joe X. Zhang
正在招募不适用NCT06838143
Ilaris NIS in Korea
South Korea
年龄 2 Years – 100 Years
Novartis Pharmaceuticals